Visual Inspection (Manual)

Manual Visual Inspection (MVI) is a fundamental, non-destructive compendial method for the quality control of 100% of manufactured parenteral drug products. It serves as a critical release and stability test designed to ensure that each unit is "essentially free of visible particulates" and that the solution's color and clarity meet established specifications. The method's effectiveness relies heavily on the rigorous training, qualification, and visual acuity of the human analyst performing the test under controlled environmental conditions. MVI remains the established compendial reference method, and automated visual inspection (AVI) systems are typically validated by demonstrating concordance with qualified MVI.

• Legacy: Inspection was performed on a standard lab bench using uncontrolled ambient lighting. This lack of standardization produced inconsistent and unreliable results.
• Gold Standard (Current): The current industry standard is the qualified manual inspection booth. This station provides controlled, high-intensity lighting (2000–3750 lux) against defined black-and-white backgrounds. Rigorously trained analysts, qualified with standardized defect kits, perform the inspection.
• Future: The industry is moving towards semi-automated and fully-automated visual inspection (AVI) systems to reduce operator subjectivity. AVI uses advanced cameras and machine learning for high-speed, repeatable defect detection. Manual Visual Inspection (MVI) remains the essential benchmark for validating and qualifying all AVI systems.

The method leverages the unique capabilities of human vision to detect visible anomalies in a liquid solution within its final container. By swirling the container and viewing it against contrasting black and white backgrounds under high-intensity, non-glaring light, an analyst can identify mobile, undissolved particles and assess the solution's color and clarity. The black background makes light-colored or translucent particles (like fibers and glass) visible, while the white background reveals dark-colored particles.

The data output is qualitative (pass/fail) for each unit inspected. Any unit found to contain visible particulates is rejected.

• Interpretation: The primary acceptance criterion, as defined by USP <790>, is that a batch is considered acceptable if it was subjected to 100% inspection and is "essentially free of visible particulates." This is a process-based standard, not a simple statistical sampling plan. For color and clarity, the interpretation is a direct comparison to a standard (e.g., "The solution is not more opalescent than Opalescence Standard OS2").

• Versatility: A trained analyst can inspect a vast range of products, container types (vials, syringes, ampules), and sizes with minimal changeover.
• Broad Defect Detection: Humans are exceptionally good at identifying novel or unexpected defects beyond typical particles, such as container cracks, improper seals, or cosmetic flaws.
• Regulatory Acceptance: As the established "gold standard," it is universally accepted by all regulatory agencies.
• Low Capital Cost: The initial investment for a manual inspection booth is significantly lower than for a fully automated system.

• Subjectivity: The outcome is highly dependent on the individual analyst's training, skill, visual acuity, and level of fatigue. This can lead to variability between analysts and sessions.
• Limited Detection Capability: MVI is probabilistic, not absolute. The probability of detecting a particle drops significantly for particles smaller than 50-100 µm.
• Throughput: The process is labor-intensive and relatively slow compared to automated methods.
• Ergonomic Strain: The repetitive nature of the task can cause physical strain on analysts.

• Analyst Training & Qualification: Analysts must be trained on defect recognition and then formally qualified. Qualification involves testing their ability to reliably detect known defects in a test set (often called a Knapp kit), which includes containers with particles of various types and sizes. Requalification is performed at regular intervals.
• Visual Acuity: Analysts must pass periodic eye exams, including tests for near vision and color discrimination.
• Equipment Qualification (IQ/OQ): The inspection booth and its components, particularly the light source, must be formally installed and operationally qualified to ensure they meet pharmacopeial requirements (e.g., light intensity between 2000–3750 lux).

A primary challenge of manual visual inspection is the inherent subjectivity between different analysts. To standardize this critical test, the industry relies on a combination of pharmacopeial standards and physical reference materials.

• Pharmacopeial Standards: Guidance like [USP <790> Visible Particulates in Injections] are foundational, defining the controlled environment for the test, such as the required black-and-white backgrounds and the specific light intensity (2000–3750 lux).
• Analyst Training and Qualification Standards: To qualify analysts and harmonize results, companies can use commercially available defect kits. Furthermore, to provide a certified benchmark, the National Institute of Standards and Technology (NIST) has developed Standard Reference Material (SRM) 1989. This SRM consists of irregularly shaped epoxy particles of a certified size and is designed to be used to prepare in-house standards for training and qualifying analysts on the visual inspection process for protein-like particulates.
• https://www.nist.gov/publications/certification-standard-reference-materialr-1989-monodisperse-irregularly-shaped-epoxy#:~:text=Standard%20Reference%20Material%20(SRM)%201989,of%20an%20irregularly%20shaped%20particle.

• Monoclonal Antibodies (mAbs) & Biologics: For monoclonal antibodies and biologics, MVI is critical to detect large visible aggregates or extrinsic particulates. Sub-visible protein aggregates remain a major concern for immunogenicity but require orthogonal analytical methods (e.g., light obscuration, flow imaging) for detection.
• Cell & Gene Therapies: Inspection is often required but presents unique challenges due to small batch sizes, the potential for inherent cellular material to be present, and the use of non-traditional containers like cryo-bags which have lower optical quality than glass vials.